The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease

Abstract

Excess aldosterone is associated with the increased risk of cardio-/cerebrovascular events as well as metabolic comorbidities not only due to its hypertensive effect but also due to its proinflammatory action. Autonomous cortisol secretion (ACS) in the setting of primary aldosteronism (PA) is known to worsen cardiovascular outcome and potentially exhibit immunosuppressive effects. The aim of this study was to determine the impact of ACS status in patients with PA on kinetics of thyroid autoantibodies (anti-TPO, anti-TG) pre and post therapy initiation. Ninety-seven PA patients (43 unilateral, 54 with bilateral PA) from the database of the German Conn’s Registry were included. Anti-TPO and anti-TG levels were measured pre and 6–12 months post therapeutic intervention. Patients were assessed for ACS according to their 24- hour urinary cortisol excretion, late night salivary cortisol and low-dose dexamethasone suppression test. Abnormal test results in line with ACS were identified in 74.2% of patients with PA. Following adrenalectomy, significant increases in anti-TPO levels were observed in patients with at least one abnormal test (p = 0.049), adrenalectomized patients with at least two pathological ACS tests (p = 0.015) and adrenalectomized patients with pathologic dexamethasone suppression tests (p = 0.018). No antibody increases were observed in unilateral PA patients without ACS and in patients with bilateral PA receiving mineralocorticoid antagonist therapy (MRA). Our data are in line with an immunosuppressive effect of mild glucocorticoid excess in PA on thyroid autoantibody titers. This effect is uncovered by adrenalectomy, but not by MRA treatment.

Key words

primary aldosteronism - auto-immune disease - adrenalectomy - thyroid - cortisol secretion - auto-antibodies

Publikationsverlauf

Eingereicht: 20. Dezember 2019

Angenommen: 20. April 2020

Artikel online veröffentlicht:
13. Mai 2020

• References

• 1 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 2 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 3 Born-Frontsberg E, Reincke M, Rump LC. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
• 4 Milliez P, Girerd X, Plouin PF. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
• 5 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
• 6 Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: Implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 2004; 217: 53-58
• 7 Fischer E, Adolf C, Pallauf A. et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 2513-2520
• 8 Colussi G, Catena C, Lapenna R. et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 2349-2354
• 9 Ahokas RA, Warrington KJ, Gerling IC. et al. Aldosteronism and peripheral blood mononuclear cell activation: A neuroendocrine-immune interface. Circ Res 2003; 93: e124-e135
• 10 Caturegli P, Kimura H, Rocchi R. et al. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007; 19: 44-48
• 11 Lorini R, Gastaldi R, Traggiai C. et al. Hashimoto’s Thyroiditis. Pediatr Endocrinol Rev 2003; 1 (Suppl. 02) 205-211 discussion 211.
• 12 Schirpenbach C, Segmiller F, Diederich S. et al. The diagnosis and treatment of primary hyperaldosteronism in Germany: Results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 2009; 106: 305-311
• 13 Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes 2019; 127: 84-92
• 14 Betz MJ, Degenhart C, Fischer E. et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011; 165: 301-306
• 15 Ladurner R, Sommerey S, Buechner S. et al. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur J Clin Invest 2017; 47: 372-377
• 16 Riester A, Fischer E, Degenhart C. et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E1035-E1039
• 17 Heinrich DA, Adolf C, Holler F. et al. Adrenal insufficiency after unilateral adrenalectomy in primary aldosteronism: Long-term outcome and clinical impact. J Clin Endocrinol Metab 2019; 104: 5658-5664
• 18 Herrada AA, Contreras FJ, Marini NP. et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010; 184: 191-202
• 19 Herrada AA, Campino C, Amador CA. et al. Aldosterone as a modulator of immunity: Implications in the organ damage. J Hypertens 2011; 29: 1684-1692
• 20 Shi Y, Wang H, Su Z. et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimotoʼs thyroiditis. Scand J Immunol 2010; 72: 250-255
• 21 Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007; 54: 359-370
• 22 Bendtzen K, Hansen PR, Rieneck K. et al. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151-158
• 23 Munro Neville A. MJOH. Hyperaldosteronism and Related Syndromes of Mineralocorticoid Excess. Springer; London: 1982: 202-241
• 24 Biglieri EG, Schambelan M, Slaton PE. et al. The intercurrent hypertension of primary aldosteronism. Circ Res 1970; 27: 195-202
• 25 Enberg U, Volpe C, Hoog A. et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol 2004; 151: 73-85
• 26 Nakamura Y, Felizola SJ, Satoh F. et al. Dissecting the molecular pathways of primary aldosteronism. Pathol Int 2014; 64: 482-489
• 27 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
• 28 Davis WW, Newsome HH, Wright LD. et al. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity. Am J Med 1967; 42: 642-647
• 29 Doorenbos H, Elings HS, Van Buchem FS. Primary aldosteronism due to adrenocortical hyperplasia. Lancet 1956; 271: 335-337
• 30 Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-1834
• 31 Katz FH. Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia. Ann Intern Med 1967; 67: 1035-1042
• 32 Ledingham JG, Laragh JH, Sommers SC. Secondary aldosteronism and reduced plasma renin in hypertensive disease. Trans Assoc Am Physicians 1967; 80: 168-182
• 33 Kem DC, Li H, Velarde-Miranda C. et al. Autoimmune mechanisms activating the angiotensin AT1 receptor in ‛primary’ aldosteronism. J Clin Endocrinol Metab 2014; 99: 1790-1797
• 34 Rossitto G, Regolisti G, Rossi E. et al. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. Hypertension 2013; 61: 526-533
• 35 Li H, Yu X, Cicala MV. et al. Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. J Am Soc Hypertens 2015; 9: 15-20
• 36 Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2015; 100: 1-10
• 37 Er LK, Chen L, Tsai YC. et al. Risk of new-onset autoimmune diseases in primary aldosteronism: A nation-wide population-based study. J Hypertens 2019; 38: 745-754
• 38 Piazza M, Seccia TM, Caroccia B. et al. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies): Cause or consequence of human primary aldosteronism?. Hypertension 2019; 74: 793-799
• 39 Turchi F, Ronconi V, di Tizio V. et al. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension. Am J Hypertens 2011; 24: 1274-1279
• 40 Armanini D, Nacamulli D, Scaroni C. et al. High prevalence of thyroid ultrasonographic abnormalities in primary aldosteronism. Endocrine 2003; 22: 155-160
• 41 Cioni K, Pantaleoni M, Toschi E. et al. Exacerbation of autoimmune hypothyroidism after hemi-hypophysectomy in a patient with Cushing's disease. Minerva Endocrinol 1993; 18: 139-141
• 42 Colombo P, Passini E, Re T. et al. Autoimmune thyroid disease after successful treatment of Cushing’s syndrome. J Endocrinol Invest 1994; 17: 289-290
• 43 Takasu N, Komiya I, Nagasawa Y. et al. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing’s syndrome due to an adrenocortical adenoma. N Engl J Med 1990; 322: 1708-1712
• 44 Yamakita N, Sakata S, Hayashi H. et al. Case report: Silent thyroiditis after adrenalectomy in a patient with Cushing’s syndrome. Am J Med Sci 1993; 305: 304-306
• 45 Uthman I, Senecal JL. Onset of rheumatoid arthritis after surgical treatment of Cushing’s disease. J Rheumatol 1995; 22: 1964-1966
• 46 Yakushiji F, Kita M, Hiroi N. et al. Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing’s syndrome. Endocr J 1995; 42: 219-223
• 47 Noguchi Y, Tamai H, Fujisawa K. et al. Systemic lupus erythematosus after pituitary adenomectomy in a patient with Cushing’s disease. Clin Endocrinol (Oxf) 1998; 48: 670-672
• 48 McGregor AM. Immunoendocrine interactions and autoimmunity. N Engl J Med 1990; 322: 1739-1741
• 49 Murray IP. The effect of prednisolone on Hashimoto’s thyroiditis. Scott Med J 1958; 3: 341-345
• 50 Niepomniszcze H, Pitoia F, Katz SB. et al. Primary thyroid disorders in endogenous Cushing's syndrome. Eur J Endocrinol 2002; 147: 305-311
• 51 Colao A, Pivonello R, Faggiano A. et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2000; 53: 13-19